###begin article-title 0
EMP3 Overexpression in Primary Breast Carcinomas is not Associated with Epigenetic Aberrations
###end article-title 0
###begin p 1
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
1These authors contributed equally to this work.
###end p 1
###begin p 2
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 508 509 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 512 514 512 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-7</sup>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 619 621 619 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-7</sup>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 686 687 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 694 696 694 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-6</sup>
###xml 731 735 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 909 913 909 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 994 998 994 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1064 1068 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Epithelial membrane protein 3 (EMP3) is a trans-membrane signaling molecule with important roles in the regulation of apoptosis, differentiation and invasion of cancer cells, but the detailed is largely still unknown. We analyzed the mRNA levels and methylation statuses of EMP3 in 63 primary breast carcinomas and assessed their correlations with clinicopathologic variables. The expression of EMP3 mRNA in primary breast carcinomas was significantly higher than the expression of 20 normal breast tissues (p<10-7). EMP3 overexpression in breast carcinomas was significantly related to histological grade III (p=3.9x10-7), lymph node metastasis (p=0.003), and strong Her-2 expression (p=3.3x10-6). Hypermethylation frequencies of EMP3 were detected in 36.5% of breast carcinomas by methylation-specific polymerase chain reaction. However, no significant correlations were found between methylation status of EMP3 and mRNA expression levels as well as other clinical parameters. In conclusion, EMP3 may be a novel marker of tumor aggressiveness. Overexpression of EMP3 in primary breast carcinoma is not associated with DNA methylation.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 59 64 <span type="species:ncbi:9606">women</span>
Primary breast cancer is one of the most common cancer for women. The dissemination of metastasis is the leading cause of breast cancer fatality. The metastatic process of malignant cells involves cell proliferation and cell-cell interactions, in which epithelial membrane protein 3 (EMP3) is thought to be involved (1).
###end p 4
###begin p 5
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMP22</italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMP22</italic>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP1</italic>
###xml 199 202 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TMP</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP2</italic>
###xml 211 214 211 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XMP</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 227 230 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">YMP</italic>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 439 443 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 733 738 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMP22</italic>
###xml 743 747 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP1</italic>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 944 945 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 946 947 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 908 913 <span type="species:ncbi:9606">human</span>
The myelin-related gene EMP3 belongs to the peripheral myelin protein 22-kDa (PMP22) gene family of small hydrophobic membrane glycoproteins, which include four closely related members, PMP22, EMP1 (TMP), EMP2 (XMP), and EMP3 (YMP), as well as an additional and more distant, member, MP20 (2). The EMP3 gene is located on the 19q13.3 band, which encodes a protein similar to PMP22, EMP1 and EMP2 with approximately 40% of amino acids (1). EMP3 has high transcriptional expression in peripheral blood leukocytes, ovary, intestine and various embryonic tissues (1). The function of the EMP3 protein is largely unknown. But it may be involved in regulating cell proliferation and cell-cell interactions, based on the available data for PMP22 and EMP1 which are the best-characterized members of the family (3). Recent reports showed that overexpression of EMP3 positively associated with the invasive status of human mammary carcinoma cell lines (4-6).
###end p 5
###begin p 6
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 351 355 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 823 824 823 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 919 923 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1105 1109 1105 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1227 1231 1227 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 1141 1146 <span type="species:ncbi:9606">human</span>
###xml 1284 1289 <span type="species:ncbi:9606">human</span>
It has emerged that epigenetic events can lead to gene inactivation that contributes to human neoplasia. The most important mechanism in mammalian cells is DNA methylation, the covalent addition of a methyl group to the 5'position of cytosine, predominantly within the CpG dinucleotide (7). An online search for CpG islands () in the 5' region of the EMP3 gene (GenBank accession number, NM001425) revealed a typical CpG island on the start site of the transcripton. It indicated that hypermethylation of the promoter regions of EMP3 likely plays an important role in the regulation of their mRNA levels in malignant tumors. Alaminos et al. (8) showed that the hypermethylation of the promoter region of the EMP3 gene was present in 24% of 116 neuroblastic primary tumors and 39% of 41 gliomas. On the contrary, Li et al. (9) recently reported that methylation alone does not mediate transcriptional down-regulation of EMP3 in oligodendroglial tumors, because their study with 29 oligodendroglial tumors showed no correlation between transcript level and methylation status. The methylation status of the EMP3 gene is still unknown in other human tumors. In the present study, we tried to analyze the methylation status of the EMP3 gene as well as its correlation with mRNA levels in human primary breast carcinoma.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Tissue samples
###end title 8
###begin p 9
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
###xml 915 923 <span type="species:ncbi:9606">patients</span>
###xml 1042 1050 <span type="species:ncbi:9606">patients</span>
Primary breast carcinoma samples (n=63) and normal breast tissues (n=20) were obtained from patients who were diagnosed with T1-T3, N0-N2 (stage I-IIIA) breast carcinoma and had been treated with curative resectional surgery between June 2004 and March 2006, in Shandong Cancer Hospital and Institute (Jinan, China). Among them, 9 patients had stage I, 25 patients had stage IIA, 13 patients had stage IIB, and 16 patients had stage IIIA disease. The median age of the patients was 51 yr (range, 32-80). There were 34 node-negative and 29 node-positive patients (12 with one to three positive nodes, and 17 with more than three positive nodes). Histological subtypes included 43 invasive ductal, 6 invasive lobular, 6 mixed type (ductal/lobular), 7 mucinous carcinomas and 1 ductal carcinoma in situ, which were classified according to the WHO classification (10). All the breast tissue samples were collected from patients, who had neither chemotherapy nor radiotherapy before operation. They were collected with the informed consent of all patients. The study was approved by the ethics committees of Shandong Cancer Hospital. The collected specimens were snap-frozen in liquid nitrogen and kept at -80℃.
###end p 9
###begin title 10
Immunohistochemical analysis
###end title 10
###begin p 11
###xml 546 551 <span type="species:ncbi:10090">mouse</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
###xml 681 686 <span type="species:ncbi:10090">mouse</span>
###xml 692 697 <span type="species:ncbi:9606">human</span>
###xml 798 803 <span type="species:ncbi:10090">mouse</span>
###xml 809 814 <span type="species:ncbi:9606">human</span>
###xml 899 904 <span type="species:ncbi:10090">mouse</span>
###xml 910 915 <span type="species:ncbi:9606">human</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
###xml 1026 1031 <span type="species:ncbi:9606">human</span>
Standard immunohistochemical detection, with minor modifications, was performed with archival paraffin embedded breast tumor tissues and corresponding nonmalignant breast tissues. In brief, 4 microm thick histological sections were mounted on 0.1% poly-L-lysine treated slides, dried overnight at 37℃, and subsequently deparaffinized and rehydrated. Protein expressions in malignant and nonmalignant breast tissues were detected with specific antibodies against the estrogen receptor (ER) (Zymed, San Francisco, CA, U.S.A.; prediluted monoclonal mouse anti-human estrogen receptor clone 1D5, incubated for 18 hr at 4℃), the progesterone receptor (PR) (Zymed; prediluted monoclonal mouse anti-human progesterone receptor clone PR-2C5, incubated for 18 hr at 4℃), Her-2 (Zymed; prediluted monoclonal mouse anti-human Her-2 clone TAB250, incubated for 30 min at 37℃), p53 (Zymed; prediluted monoclonal mouse anti-human p53 protein clone BP53.12, incubated for one hour at 37℃), and Ki-67 (Zymed; prediluted monoclonal mouse anti-human Ki-67 antigen clone 7B11, incubated for one hour at 37℃). In addition, positive and negative controls for each marker were routinely performed during experiments.
###end p 11
###begin p 12
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Sections were then processed using the Histostain-SP kits according to the manufacturer's recommendations (Zymed). Interpretation of the staining was carried out according to the usual criteria (11) by two independent blinded observers. If any discrepancies between classifications of samples arose, they were reviewed and the final results reached by consensus. In brief, ER, PR, and p53 were scored for the immunohistochemical signal as follows: weak (1+), moderate (2+), and strong (3+) staining in >10% of the tumor cells or absent (0). Levels of Her-2 protein expression were evaluated semi-quantitatively using Zymed evaluation guidelines, as follows: no staining or membrane staining in less than 10% of the tumor cells (0), weak, incomplete membrane staining in more than 10% of the tumor cells (1+), weak or moderate complete membrane staining in more than 10% of the tumor cells (2+), and strong, complete membrane staining in more than 10% of the tumor cells (3+). Further, for Ki-67 expression we evaluated the percentage of cells stained.
###end p 12
###begin title 13
RNA extraction and reverse transcription
###end title 13
###begin p 14
Total RNA was extracted from frozen tissues using the Trizol reagent (Invitrogen, Carlsbad, CA, U.S.A.) following the manufacturer's instructions. RNA was treated with DNase and purified using the RNeasy mini kit (Qiagen, Hilden, Germany). Purified RNA was eluted in 30 microL of the RNA storage solution (Ambion, Austin, TX, U.S.A.) and stored at -80℃. The total RNA was quantified by UV-spectroscopy (U-3000 Spectrophotometer, Hitachi, Tokyo, Japan). cDNA synthesis was conducted using the high capacity cDNA archive kit (Applied Biosystems, Foster City, CA, U.S.A.) according to the manufacturer's instructions. The cDNA samples were used for reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.
###end p 14
###begin title 15
Semi-quantitative RT-PCR
###end title 15
###begin p 16
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 868 870 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
The primers of EMP3 gene were designed by the software of Primer 5 according to the Gene Bank sequence (NM 001425). The upward and downward primers were designed to span two exons to avoid any amplification of genomic DNA. The primer pairs of EMP3 were 5'-CGA GAA TGG CTG GCT GAA G-3', 5'-GCC ACG CTG GTG CAA AG-3', (156 bp). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was also amplified in the same PCR reactions as an internal control using the following primers: 5'-GAA GGT GAA GGT CGG AGT C-3', 5'-GAA GAT GGT GAT GGG ATT TC-3', (226 bp, designed by Applied Biosystems). For semi-quantitative RT-PCR analysis, 1 microL of cDNA was added in a tube containing 10xReaction Buffer 1 microL, 4x10 mM dNTP 0.4 microL, 10 microM of each primer 0.5 microL, 5 U/microL Taq DNA polymerase 0.1 microL (Promega, Madison, WI, U.S.A.) in a final volume of 10 microL (12). Cycling conditions were denaturation at 94℃ for 5 min, then 35 cycles of PCR (94℃, 30 sec; 60℃, 30 sec; and 72℃, 30 sec), followed by a final extension of 72℃ for 10 min. The amplification products were resolved by 3% agarose gel electrophoresis and visualized by ethidium bromide staining.
###end p 16
###begin title 17
Quantitative real-time PCR
###end title 17
###begin p 18
###xml 485 486 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 930 931 883 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1380 1382 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1427 1440 1380 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-&#916;&#916;CT</sup>
###xml 1544 1545 1489 1490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1694 1695 1635 1636 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1724 1725 1661 1662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1727 1728 1664 1665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1744 1745 1681 1682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1806 1807 1735 1736 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1814 1815 1739 1740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1837 1838 1758 1759 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
Quantitative real-time PCR was carried out using the specific primers as mentioned above. GAPDH mRNA was also amplified as an internal control. Briefly, 2 microL of cDNA was used to determine gene expression levels by the ABI PRISM(R) 7000HT Sequence Detection Systems (Applied Biosystems). It was amplified in the 25 microL reaction including 2xSYBR Premix Ex Taqtrade mark 12.5 microL (Takara, Shiga, Japan), 10 microM of each primer 0.5 microL, 50xROX Reference Dye 0.5 microL and H2O 9 microL. Cycling conditions included a hot start (15 sec, 95℃), followed by 40 cycles of 95℃, 10 sec and 60℃, 40 sec. For analysis, a threshold was set for the change in fluorescence at a point in the linear PCR amplification phase. Melt curve analysis was performed to ensure a single product species. All experiments were done in duplicate for both target gene and internal control and repeated three independent times. For the DeltaDeltaCT calculation to be valid, the amplification efficiencies of the target and reference must be approximately equal. The standard curves used to determine relative expression were obtained by running real-time PCR for a diluted sample, for example, to 1:1, 1:10, 1:100, and 1:1,000. After control for equal PCR efficiency of target genes and internal controls, relative gene expressions were presented with the comparative Ct method of quantification (13). Briefly, this technique uses the formula 2-DeltaDeltaCT to calculate the relative expression of target genes normalized to a calibrator. The threshold cycle (CT) indicates the cycle number at which the amount of amplified target reaches a fixed threshold. The level of genes was calculated by comparing DeltaCT values of the sample (DeltaCT=CT [target gene]-CT [GAPDH gene]) to that of the calibrator; that is DeltaDeltaCT=DeltaCT (tumor sample)-DeltaCT (calibrator).
###end p 18
###begin title 19
DNA preparation and sodium bisulphate modification
###end title 19
###begin p 20
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
Genomic DNA from tissue specimens was isolated according to a standard proteinase K digestion and phenol/chloroform extraction protocol with some modifications (14). In brief, the materials were grounded to a fine powder under liquid nitrogen. Frozen pulverized powders of the specimens were incubated overnight at 52℃, in 500 microL lytic solution (10 mM Tris-HCl pH 8.0, 0.1 M EDTA, 0.5% SDS) containing proteinase K (Roche, Indianapolis, IN, U.S.A.). These were followed by extraction with equal volumes of phenol: chloroform:isoamyl alcohol (25:24:1). DNA was ethanol precipitated at -20℃, washed with 70% ethanol, dried and resuspended in TE buffer. The DNA concentrations were calculated according to the OD 260 nm readings.
###end p 20
###begin p 21
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
For DNA methylation analysis, sodium bisulfite modification of genomic DNA was performed, as described previously with minor modifications (15). Briefly, 1 microg of genomic DNA was denatured at 42℃ for 30 min, in a total volume of 50 microL containing NaOH (final concentration, 0.2 M). After the addition of 30 microL freshly prepared 10 mM hydroquinone (Sigma, St. Louis, MO, U.S.A.) and 520 microL of 3 M sodium bisulfite (Sigma) at pH 5.0, the samples were incubated 16 hr at 55℃ in the dark. Afterward, modified DNA was purified using Wizard DNA clean-up resin (Promega A7280), and DNA was desulfonated in 0.3 M NaOH at 37℃ for 15 min. Treatment of genomic DNA with sodium bisulfite converts unmethylated cytosines (but not methylated cytosines) to uracil, which are then converted to thymidine during the subsequent PCR step, giving sequence differences between methylated and unmethylated DNA. The converted DNA was precipitated at -20℃, overnight in ice-cold 100% ethanol containing ammonium acetate (final concentration, 3 M) and 10 microg of glycogen. DNA was resuspended in deionized water, and used immediately or stored at -20℃.
###end p 21
###begin title 22
Methylation-specific PCR (MSP)
###end title 22
###begin p 23
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1517 1521 1485 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Bisulfite-modified DNA was amplified with primers specific for methylated or unmethylated sequences. The methylated-specific and unmethylated-specific primers (8) covered the transcription start site of EMP3. The methylated DNA of EMP3 (144 bp) was amplified using M set primers, 5'-GAC GTA GAA GGA GAG CGA GC-3'(sense), 5'-CCT CGC TCG AAC CTC CGT A-3'(antisense), and the unmethylated DNA of EMP3 (149 bp) was amplified using U set primers, 5'-GAA GAG ATG TAG AAG GAG AGT GAG T-3'(sense), 5'-CTT ATC CCT CAC TCA AAC CTC CAT A-3'(antisense). The PCR mixture contained 2xGC buffer 5 microL (Takara), 4x10 mM dNTP 0.4 microL, 10 microM of each primer 0.5 microL, 5 U/microL Takara LA Taq DNA polymerase 0.1 microL (Takara), and 2 microL bisulfite-modified DNA. Amplification was carried out as follows: after initial denaturation at 95℃ for 5 min, 40 cycles of amplification at 95℃ for 30 sec, 58℃ (methylated or unmethylated) for 30 sec, and 72℃ for 30 sec, followed by a final extension of 72℃ for 10 min. DNA from peripheral blood lymphocytes of healthy individuals was used as a positive control for unmethylated alleles. DNA from peripheral normal blood lymphocytes treated in vitro with SssI methyltransferase (New England Biolabs, Ipswich, MA, U.S.A.) was used as a positive control for methylated alleles. Ten microL of each PCR reaction were loaded and run onto 3% agarose gels stained with ethidium bromide and visualized under UV illumination. The PCR for all samples demonstrating methylation status of the EMP3 gene was repeated to confirm these results.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 871 875 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 985 986 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 98 105 <span type="species:ncbi:9606">patient</span>
Descriptive statistics, such as mean, standard deviation, and percentage were used to summarize a patient's data and gene expression or methylation status. The immunohistological markers were defined into dichotomous variables on the basis of the staining index such as negative/reduced expression levels (scores 0, 1, and 2) and positive/maximum staining (score 3) for ER, PR, Her-2 proteins. To p53 protein, the expression level was categorized as negative (scores 0 and 1) or positive (scores 2 and 3). The comparison of EMP3 mRNA levels among various subgroups such as tumor sizes, histologic grade, and lymph node status was calculated using the Kruskal-Wallis test. The EMP3 mRNA expression levels between different sex, immunohistological, and methylation status teams were evaluated by using the Mann-Whitney test. The correlations of the methylation statuses of EMP3 with clinicopathologic parameters were analyzed by chi-square test. Statistical significance was assumed for p<0.05. The statistical tests were performed using the statistical software package SPSS, version 12.0 (LEAD Technologies, Athens, GA, U.S.A.).
###end p 25
###begin title 26
RESULTS
###end title 26
###begin title 27
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Correlation of EMP3 mRNA levels with clinicopathologic parameters in primary breast carcinoma
###end title 27
###begin p 28
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 135 142 135 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1A</xref>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 413 420 413 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 440 444 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 553 554 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 557 559 557 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-7</sup>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 677 678 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 685 687 685 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-7</sup>
###xml 713 714 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 752 753 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 760 762 760 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-6</sup>
###xml 905 909 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
The mRNA levels of EMP3 were analyzed in all the 63 primary breast carcinomas and the 20 normal breast tissues by conventional RT-PCR (Fig. 1A). The results showed that the mRNA of EMP3 was over-expressed in breast carcinomas as compared with in normal breast tissues. EMP3 expression status determined by real-time PCR assay is shown according to the various clinical, pathological, and biological parameters in Table 1. The expression of EMP3 mRNA in primary breast carcinomas was significantly higher than the expression of 20 normal breast tissues (p<10-7). Furthermore, EMP3 overexpression in primary breast carcinomas was significantly related to histological grade III (p=3.9x10-7), lymph node metastasis (p=0.003), and strong Her-2 expression (p=3.3x10-6). Other parameters such as age, menopausal status, histological subtype and macroscopic tumor size did not show significant correlations with EMP3 mRNA levels.
###end p 28
###begin title 29
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
The methylation statuses of EMP3 and their correlation with clinical-pathological data in primary breast carcinoma
###end title 29
###begin p 30
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 185 192 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1B</xref>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 586 593 586 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
The frequencies of methylation of EMP3 were determined in the 63 resected primary breast carcinomas and in the 20 corresponding nonmalignant breast tissues by methylation-specific PCR (Fig. 1B). Twenty-three of 63 (36.5%) tumors showed EMP3 methylation. In the normal breast tissues, methylation of EMP3 was not detected. The incomplete methylation form of EMP3 was detected in 82.6% (19/23) of methylated samples in breast carcinomas. Statistical analysis showed that there were no significant links between methylation frequencies and clinical, pathological or biological parameters (Table 2).
###end p 30
###begin title 31
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Relationship of methylation statuses of EMP3 with their mRNA levels in primary breast carcinoma
###end title 31
###begin p 32
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 541 542 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 666 672 662 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
Of the 23 breast carcinomas exhibiting hypermethylation at the promoter region of EMP3, 1 (4.3%) showed low expression level, and 22 (95.7%) exhibited high EMP3 expression levels when compared to normal breast tissues. Of the 40 breast carcinomas which the promoter region of EMP3 was unmethylated, 3 (7.5%) showed expression levels similar to the normal samples, and 37 (92.5%) showed high expression levels of EMP3 compared with the control samples where EMP3 was also unmethylated. The Mann-Whitney test showed no significant difference (p=0.418) of EMP3 expression levels between CXCL12 methylated (2.59+/-2.30) and unmethylated breast carcinomas (2.13+/-1.91) (Fig. 2).
###end p 32
###begin title 33
DISCUSSION
###end title 33
###begin p 34
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 695 699 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 814 818 814 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 927 928 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 931 933 931 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-7</sup>
###xml 936 940 936 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1163 1167 1163 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1261 1262 1261 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1263 1264 1263 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1271 1275 1271 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1457 1458 1457 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1504 1508 1504 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1549 1553 1549 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 282 291 <span type="species:ncbi:10090">nude mice</span>
###xml 1225 1230 <span type="species:ncbi:9606">human</span>
Recently, the EMP3 gene was reported to have reduced transcriptional expression in primary neuroblastoma, an extracranial malignant solid tumor of childhood (8). Reintroduction of EMP3 in deficient neuroblastoma cell lines induced lower colony formation density and tumor growth in nude mice (8). Thus, Alaminos et al. proposed that the EMP3 gene, located on chromosome 19q13, is a candidate tumor suppressor gene in neuroblastomas (8). In the present study, we used real-time quantitative RT-PCR assays to determine the mRNA expression levels of EMP3 in tumors different from neuroblastoma in tissue origin and age of onset: primary breast carcinoma. Meanwhile, we sought relationships between EMP3 expression status and clinical, pathological, and biological parameters. However, we found that the expression of EMP3 mRNA in primary breast carcinomas was significantly higher than the expression of 20 normal breast tissues (p<10-7). EMP3 overexpression in primary breast carcinomas was significantly related to histological grade III, lymph node metastasis and strong Her-2 expression. These data are consistent with reports indicating that overexpressions of EMP3 are significantly associated with the invasive status of human mammary carcinoma cell lines (3-6). The EMP3 gene was found to be significantly up-regulated (>2.0-fold) in the Her-2-overexpressing breast cancer cell line as compared with in the normal mammary luminal epithelial cell line (4). Taken together with previous studies about EMP3 expression status, we hypothesized that EMP3 may display different expression pattern in different histopathological tumors.
###end p 34
###begin p 35
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP-1</italic>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP-2</italic>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMP-22</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMPs</italic>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 596 600 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP1</italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMP-22</italic>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 690 691 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 719 723 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 925 929 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Until now, the studies on the EMP3 gene are rarely reported and its function is largely still unknown. Recent evidence indicates that EMP3 may participate in the process of cell apoptosis (16). EMP3 as well as the other members of the epithelial membrane protein family (EMP-1, EMP-2, and PMP-22) was found to be expressed in HEK-293 cells, which also express P2X7 receptors. The constitutive overexpression of any of the EMPs in HEK-293 cells, through its interaction with P2X7 receptor, led to cell blebbing, annexin V binding, and cell death by a caspase-dependent pathway (16). Nevertheless, EMP1, PMP-22, and EMP3 were found to be highly expressed in invasive mammary carcinoma cells (3, 6, 17). Thus, the role of EMP3, whether as a candidate tumor suppressor gene or an indicator of tumor progression, remains to be established. Absence of the unitary conception of EMP3 behavior requires a comprehensive assessment of EMP3 expression and functional mechanism in different histopathological tumors.
###end p 35
###begin p 36
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 439 443 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 679 683 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 811 812 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1004 1008 1004 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1040 1044 1040 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
We sought to define a possible mechanism regulating the expression of EMP3. Epigenetic events such as DNA methylation are thought to be a major early event in tumor development (18). A main target of the regional hypermethylation is normally CpG islands located in gene promoter regions. The 5' region of the EMP3 gene revealed a typical CpG island on the start site of the transcripton. We subsequently analyzed the methylation status of EMP3 and its relationship with mRNA expression in primary breast carcinoma. We found that EMP3 was hypermethylated 36.5% in 63 primary breast carcinomas. But we did not find significant statistical correlation between methylation status of EMP3 and EMP3 expression level as well as histologic subtype, tumor grade, age and gender. Consistent with our findings, Li et al. (9) reported that no correlation was found between transcript level and methylation status in oligodendroglial tumors, though all oligodendroglial tumors except 3 showed aberrant methylation of EMP3. Taken together, links between EMP3 methylation status and the mode of its expression in different tumors need further study.
###end p 36
###begin p 37
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 715 719 715 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1053 1057 1053 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
In addition to the role of DNA methylation, other regulatory mechanisms may be involved in the regulation of EMP3. Burmester et al. (19) tested candidate SNPs from genomic regions that show linkage to prostate cancer susceptibility and/or aggressiveness. The polymorphism in EMP3 changes amino acid 125 from Val to Ile (19). Significant difference (p<0.0001) in allele frequencies of SNP was observed for EMP3 between prostate cancer sibships and controls (19). And the association remained significant when cases and controls were matched for age (19). In addition, Li et al. (9) reported that EMP3 overexpression was associated with oligodendroglial tumors retaining chromosome arms 1p and 19q, whereas decreased EMP3 expression was associated with deletion of chromosome 1p, not 19q. However, this notion is at variance with the study from Kunitz et al. (20). They found that low EMP3 expression was significantly associated with 19q deletion in oligodendroglial tumors, but not in astrocytic tumors (20). Obviously, the real regulatory mechanism of EMP3 expression remains to be elucidated. Given the variable expression patterns of EMP3 in different malignant tumors, the pathway leading to this diversity may also be quite different, which needs to be further investigated by additional genetic or biochemical studies.
###end p 37
###begin title 38
ACKNOWLEDGMENTS
###end title 38
###begin p 39
###xml 105 112 <span type="species:ncbi:9606">patient</span>
We thank the staff of the Breast Cancer Center, Shandong Cancer Hospital and Institute for assistance in patient care and specimen collection. We also thank Xiaotian Chang, of Shandong Academy of Medical Sciences, for writing assistance.
###end p 39
###begin p 40
###xml 39 77 39 77 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Natural Science Foundation of Shandong</funding-source>
###xml 79 91 79 91 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2006ZRC03115</award-id>
###xml 96 104 96 104 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y2005C39</award-id>
###xml 123 189 123 189 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National High Technology Research and Development Program of China</funding-source>
###xml 205 217 205 217 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2007AA02Z437</award-id>
This study was supported partly by the Natural Science Foundation of Shandong, 2006ZRC03115 and Y2005C39 and partly by the National High Technology Research and Development Program of China (863 Program), 2007AA02Z437.
###end p 40
###begin article-title 41
Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family
###end article-title 41
###begin article-title 42
Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22
###end article-title 42
###begin article-title 43
Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins
###end article-title 43
###begin article-title 44
###xml 85 90 <span type="species:ncbi:9606">human</span>
cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells
###end article-title 44
###begin article-title 45
###xml 63 68 <span type="species:ncbi:9606">human</span>
Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling
###end article-title 45
###begin article-title 46
###xml 32 37 <span type="species:ncbi:9606">human</span>
Differential gene expression in human mammary carcinoma cells: identification of a new member of a receptor family
###end article-title 46
###begin article-title 47
DNA methylation, methyltransferases, and cancer
###end article-title 47
###begin article-title 48
EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma
###end article-title 48
###begin article-title 49
EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q
###end article-title 49
###begin article-title 50
CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer
###end article-title 50
###begin article-title 51
Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer
###end article-title 51
###begin article-title 52
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 52
###begin article-title 53
###xml 66 71 <span type="species:ncbi:9606">human</span>
Purification of DNA from formaldehyde fixed and paraffin embedded human tissue
###end article-title 53
###begin article-title 54
Bisulfite genomic sequencing: systematic investigation of critical experimental parameters
###end article-title 54
###begin article-title 55
Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus
###end article-title 55
###begin article-title 56
Expression analysis of tho PMP22 gene in glioma and osteogenic sarcoma cell lines
###end article-title 56
###begin article-title 57
Alterations in DNA methylation: a fundamental aspect of neoplasia
###end article-title 57
###begin article-title 58
Analysis of candidate genes for prostate cancer
###end article-title 58
###begin article-title 59
###xml 76 81 <span type="species:ncbi:9606">Human</span>
DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas
###end article-title 59
###begin p 60
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TB</italic>
###xml 240 242 240 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NB</italic>
###xml 246 247 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TB</italic>
Expression and methylation analyses of EMP3 in primary breast carcinomas. (A) Semi-quantitative RT-PCR analysis showing EMP3 mRNA is over-expressed in primary breast carcinoma (TB) as compared with their corresponding nonmalignant tissues (NB). (B) Methylation analysis of EMP3 in primary breast carcinomas (TB) by methylation-specific PCR.
###end p 60
###begin p 61
###xml 51 52 51 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 54 55 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Lane U, unmethylated; Lane M, methylated. Data in (A, B) are representative of two independent experiments.
###end p 61
###begin p 62
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UM</italic>
EMP3 mRNA levels were assayed by real-time PCR and compared between tumors with hypermethylation (M) and without hypermethylation (UM).
###end p 62
###begin p 63
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
Expression of EMP3 in 63 primary breast carcinomas according to the clinical, histological, or biological variables
###end p 63
###begin p 64
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 20 26 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*Mann-Whitney test; daggerKruskal-Wallis test.
###end p 64
###begin p 65
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
EMP3, epithelial membrane protein 3; ER, estrogen receptor; PR, progesterone receptor.
###end p 65
###begin p 66
EMP3 promoter methylation distribution according to clinical variables and immunohistochemical analysis in the 63 primary breast carcinomas
###end p 66
###begin p 67
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 26 27 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
*p value obtained from chi2 test.
###end p 67
###begin p 68
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMP3</italic>
EMP3, epithelial membrane protein 3; ER, estrogen receptor; PR, progesterone receptor.
###end p 68

